Clinical trials: Patients With Tumor
Advanced Solid Tumor
Phase I Clinical Study of YL-15293 in Patients With Advanced Solid Tumor With KRAS Mutation
This is a phase 1 / 2 open label multicenter study to evaluate the maximum tolerance, safety, tolerance and PK of oral YL-15293 in patients with advanced solid tumors with KRAS mutation, so as to confirm the recommended phase 2…
- Trial name
- NCT05173805
- Testing
- YL-15293
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Shanghai YingLi Pharmaceutical Co. Ltd.
Acute Myeloid Leukemia
Everolimus (RAD001) in Elderly Patients With Acute Myeloid Leukemia
The main goal of this study is to assess the safety and tolerability of RAD001 in combination with low-dose cytarabine in acute myeloid leukemia patients unfit for intensive chemotherapy.
- Trial name
- NCT00636922
- Testing
- RAD001(Everolimus)
- Where
- Australia
- Volunteers
- 40 people
- Sponsor
- Bayside Health
Ependymoma
Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205
Participants that were assigned to the oral etoposide treatment arm in protocol OSI-774-205 and either progressed while on study or discontinued due to unacceptable toxicity related to etoposide were allowed to participate in…
- Trial name
- NCT01247922
- Testing
- Erlotinib
- Where
- 21 sites in United States, Canada and 1 more
- Volunteers
- 4 people
- Sponsor
- OSI Pharmaceuticals
Prostatic Neoplasms, Lymphatic Metastasis
MR-Lymphography and Lymph Node Staging in Prostate Cancer
This proposal is targeted at all patients with prostate cancer who are candidates for either curative surgery or curative radiotherapy in whom lymph node staging is indicated.
- Trial name
- NCT00185029
- Testing
- Ferumoxtran-10 enhanced MRI (MRL)
- Where
- 3 sites in Netherlands
- Volunteers
- 396 people
- Sponsor
- Radboud University Medical Center
Good Prognosis Metastatic Gestational Trophoblastic Tumor, Hydatidiform Mole
Methotrexate Compared With Dactinomycin in Treating Patients With Gestational Trophoblastic Neoplasia
Randomized phase III trial to compare the effectiveness of methotrexate with that of dactinomycin in treating patients who have gestational trophoblastic neoplasia.
- Conditions
- Good Prognosis Metastatic Gestational Trophoblastic Tumor, Hydatidiform Mole, Non-Metastatic Gestational Trophoblastic Tumor, Uterine Corpus Choriocarcinoma
- Trial name
- NCT00003702
- Testing
- Dactinomycin, Methotrexate
- Where
- United States
- Volunteers
- 240 people
- Sponsor
- Gynecologic Oncology Group
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome
Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation
The purpose of this Phase I, multicenter study is to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-881 in advanced hematologic malignancies that harbor an IDH1 and/or IDH2 mutation
- Conditions
- Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome, Hematologic Malignancies
- Trial name
- NCT02492737
- Testing
- AG881
- Where
- 6 sites in United States, France
- Volunteers
- 46 people
- Sponsor
- Agios Pharmaceuticals, Inc.
Abdominal Pain
Effect of tDCS on Chronic Abdominal Visceral Pain in HCC Patients
To evaluate the effect of transcranial direct current stimulation (tDCS) applied to the motor cortex to reduce chronic abdominal visceral pain in a group of participants with hepatocellular carcinoma
- Trial name
- NCT02928237
- Testing
- transcranial direct current stimulation tDCS
- Volunteers
- 40 people
- Sponsor
- Assiut University
Cancer
A Study of LY2801653 in Advanced Cancer
Part A- The purpose of this study is to determine a safe dose of LY2801653 to be given to participants with advanced cancer and to determine any side effects that may be associated with LY2801653 in this participant population.
- Trial name
- NCT01285037
- Testing
- LY2801653, Cetuximab, Cisplatin
- Where
- 7 sites in United States
- Volunteers
- 190 people
- Sponsor
- Eli Lilly and Company
Non-small Cell Lung Cancer
BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC
The investigators hypothesized that simvastatin may enhance sensitivity to BIBW 2992 in non-adenocarcinoma that is relatively resistant to TKIs.
- Trial name
- NCT01156545
- Testing
- BIBW 2992, simvastatin
- Where
- South Korea
- Volunteers
- 68 people
- Sponsor
- National Cancer Center, Korea
Advance Care Planning
Planning for Future Care With Patients With Advanced Cancer
Advance Care Planning (ACP) is a process where patients (and their families if appropriate) discuss with their doctors and nurses what may happen as their illness progresses, including how they (and their family) would like to be…
- Trial name
- NCT04499872
- Testing
- Advance Care Plan with Trajectory Touchpoint Technique
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- Liverpool University Hospitals NHS Foundation Trust
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
This phase II trial studies how well Avatar-directed chemotherapy works in treating patients with ovarian, primary peritoneal, or fallopian tube cancer that does not respond to platinum anti-cancer drugs.
- Conditions
- Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Trial name
- NCT02312245
- Testing
- Bevacizumab, Gemcitabine Hydrochloride, Paclitaxel
- Where
- 3 sites in United States
- Volunteers
- 13 people
- Sponsor
- Mayo Clinic
Pancreatic Cancer
CAR-NK Cells (CL-NK-001) in Pancreatic Cancer
This is a single-center, open-label, first-in-human, dose-escalation study in patients with pancreatic cancer.
- Trial name
- NCT06816823
- Testing
- CL-NK-001
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Changhai Hospital
Hepatocellular Carcinoma
A Study to Evaluate the Safety, Tolerability and Efficacy of Cabozantinib in Patients With Hepatocellular Carcinoma and Impaired Liver Function
This is an prospective, interventional, non-randomized multicenter phase II study to evaluate the safety, tolerability and efficacy of Cabozantinib as a second-line therapy (after one prior systemic therapy) in patients with…
- Trial name
- CaboCHILD (NCT04454762)
- Testing
- Cabozantinib
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Johannes Gutenberg University Mainz
Neoplasms
A Phase I Study of Intravenous Aflibercept in Combination With Docetaxel in Japanese Cancer Patients
The primary objective of this study is to determine the dose of aflibercept to be further studied in combination with docetaxel in Japanese cancer patients.
- Trial name
- NCT00545246
- Testing
- aflibercept (AVE0005), docetaxel
- Where
- 2 sites in Japan
- Volunteers
- 12 people
- Sponsor
- Sanofi
Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
STA-4783 in Combination With Paclitaxel and Carboplatin for the Treatment of Chemotherapy Naive Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)
This study is for patients who have Stage IIIb or Stage IV NSCLC and have never had chemotherapy before for their disease. The first phase of the study recently completed and for the second phase of the study patients are…
- Trial name
- NCT00088088
- Testing
- Paclitaxel, Carboplatin, STA 4783
- Where
- 19 sites in United States
- Volunteers
- 86 people
- Sponsor
- Synta Pharmaceuticals Corp.
Breast Cancer
Histology VABB-Histology Post Surgery Pilot Project (BETTY Trial)
Pilot study on patients with invasive ductal breast cancer triple negative or receptor tyrosine-protein kinase erbB-2 (HER2) overexpressed, any axillary lymphnodes status (any cN), candidates to neoadjuvant chemotherapy.
- Trial name
- BETTY (NCT04365803)
- Testing
- vacuum-assisted breast biopsy
- Where
- Italy
- Volunteers
- 22 people
- Sponsor
- European Institute of Oncology
Essential Thrombocythemia
Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance
This is a Phase 3 open-label, multicenter, randomized, active-controlled study designed to compare the efficacy and safety and tolerability of P1101 compared with ANA after 12 months of treatment as second-line therapy for…
- Trial name
- SURPASS ET (NCT04285086)
- Testing
- Ropeginterferon alfa-2b, Anagrelide
- Where
- 67 sites in United States, Canada and 6 more
- Volunteers
- 174 people
- Sponsor
- PharmaEssentia
Castration Resistant Prostatic Cancer, Metastatic Prostate Cancer
Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects
This is a multicenter phase 2 open label study of pembrolizumab in patients with metastatic castrate resistant prostate cancer (mCRPC) with or without DNA damage repair defects.
- Trial name
- NCT03248570
- Testing
- Pembrolizumab, Chemotherapy
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of California, San Francisco
Adult Solid Neoplasm, Toxicity
Geriatric Assessment Intervention for Reducing Toxicity in Older Patients With Advanced Cancer
This cluster randomized clinical trial compares a geriatric assessment intervention with usual care for reducing cancer treatment toxicity in older patients with cancer that has spread to other places in the body.
- Conditions
- Adult Solid Neoplasm, Toxicity, Lymphoma
- Trial name
- NCT02054741
- Testing
- Comprehensive Geriatric Assessment, Quality-of-Life Assessment, Survey Administration
- Where
- 23 sites in United States
- Volunteers
- 733 people
- Sponsor
- Supriya Mohile
Hepatocellular Carcinoma
Study of Anlotinib After Lenvatinib in Patients With Hepatocellular Carcinoma
This clinical study evaluates the efficacy and safety of anlotinib in patients with hepatocellular carcinoma who have progressed on lenvatinib treatment.
- Trial name
- ALTER-H-002 (NCT04080154)
- Testing
- Anlotinib
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Shanghai Zhongshan Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.